Live Breaking News & Updates on Depei wu

Stay informed with the latest breaking news from Depei wu on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Depei wu and stay connected to the pulse of your community

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

The protein HOXA9 is overexpressed in most acute myeloid leukemia (AML) cases and is associated with poor patient outcomes.

Peng-xu , Jiangsu , China , Shenzhen , Guangdong , Hong-liu , Liusheng , Jianxiang-zhang , Xinfeng-chen , Zhenling-liu , Chunliang-li , Yingcai-jin

St. Jude Reveals Dual RBM5 Function and AML Therapy Potential

St. Jude Reveals Dual RBM5 Function and AML Therapy Potential
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Peng-xu , Jiangsu , China , Hong-liu , Guangdong , Liusheng , Shenzhen , Beisi-xu , Judith-hyle , Wojciech-rosikiewicz , Xue-yang , Feiqiu-wen

HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia

HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

Peng-xu , Jiangsu , China , Hong-liu , Guangdong , Shenzhen , Liusheng , Wojciech-rosikiewicz , Chunliang-li , Xue-yang , Xinfeng-chen , Feiqiu-wen

HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia

HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

Peng-xu , Jiangsu , China , Hong-liu , Guangdong , Shenzhen , Liusheng , Feiqiu-wen , Yingcai-jin , Depei-wu , Xue-yang , Chunliang-li

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tianjin , China , Sichuan , Gansu , Jilin , Shanghai , Macau , Peking , Beijing , Tongji , Taiwan , Soochow-university

Antengene Announces Commercial - GuruFocus.com

GuruFocus Article or News written by PRNewswire and the topic is about:

Australia , Tongji , Sichuan , China , Huazhong , Hubei , Shanghai , Hong-kong , Zhejiang , Singapore , Henan , Beijing

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Australia , Tongji , Sichuan , China , Huazhong , Hubei , Shanghai , Hong-kong , Zhejiang , Singapore , Henan , Beijing

Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing...

China , Australia , Shanghai , New-zealand , South-korea , Israel , Israeli , Jay-mei , Asia-pacific , Depei-wu , Karyopharm-therapeutics-inc , Antengene-corporation

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China,
added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for the treatment of relapsed myeloma.

Sadal , Kyongsang-bukto , South-korea , Australia , New-zealand , Hong-kong , Israel , Singapore , Beijing , China , Israeli , Chinese